We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+23.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.39B
AUM Growth
+$47.2M
(+2%)
Cap. Flow
-$369M
Cap. Flow
% of AUM
-15.45%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
68
New
22
Increased
12
Reduced
15
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$125M |
| 2 |
Cigna
CI
|
+$89.6M |
| 3 |
AbbVie
ABBV
|
+$75.2M |
| 4 |
Danaher
DHR
|
+$61M |
| 5 |
HCA Healthcare
HCA
|
+$59.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$143M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$132M |
| 3 |
Teleflex
TFX
|
+$119M |
| 4 |
Labcorp
LH
|
+$84.7M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$82.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aurinia Pharmaceuticals
AUPH
$1.93B
| $154M | 6.47% |
9,501,398
-262,522
| -3% | -$4.2M |
|
|
2
Becton Dickinson
BDX
$45.6B
| $145M | 6.08% |
621,632
+519,132
| +506% | +$125M |
|
3
Madrigal Pharmaceuticals
MDGL
$11.4B
| $136M | 5.68% |
1,197,884
-204,366
| -15% | -$20.1M |
|
|
4
AbbVie
ABBV
$455B
| $129M | 5.42% |
1,317,570
+853,670
| +184% | +$75.2M |
|
|
NVRO
5
DELISTED
NEVRO CORP.
NVRO
| $126M | 5.28% |
1,054,103
-698,517
| -40% | -$82.8M |
|
|
6
Labcorp
LH
$25.9B
| $92M | 3.86% |
644,868
-611,933
| -49% | -$84.7M |
|
|
7
Cigna
CI
$76.1B
| $88.6M | 3.71% |
+472,360
| New | +$89.6M |
|
8
Medtronic
MDT
$110B
| $83.9M | 3.52% |
915,440
+582,110
| +175% | +$55.8M |
|
|
9
HCA Healthcare
HCA
$85.7B
| $77.8M | 3.26% |
801,290
+571,560
| +249% | +$59.4M |
|
10
IQVIA
IQV
$39.1B
| $77.3M | 3.24% |
544,790
+66,210
| +14% | +$8.97M |
|
11
Encompass Health
EHC
$11B
| $77.2M | 3.23% |
1,566,749
-351,193
| -18% | -$19M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $74.8M | 3.13% |
666,510
+518,240
| +350% | +$55M |
|
13
LivaNova
LIVN
$4.45B
| $69.6M | 2.91% |
1,445,500
+219,610
| +18% | +$11M |
|
14
UnitedHealth
UNH
$383B
| $67.7M | 2.84% |
229,650
+58,820
| +34% | +$16.9M |
|
|
15
Danaher
DHR
$138B
| $66.6M | 2.79% |
+424,878
| New | +$61M |
|
16
Bristol-Myers Squibb
BMY
$132B
| $62.5M | 2.62% |
1,062,500
+888,140
| +509% | +$53.1M |
|
17
Amgen
AMGN
$209B
| $61.1M | 2.56% |
+259,200
| New | +$59.1M |
|
18
Abbott
ABT
$183B
| $58.3M | 2.44% |
+638,180
| New | +$57.7M |
|
19
Guardant Health
GH
$20.2B
| $58.3M | 2.44% |
+718,840
| New | +$57.9M |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $58M | 2.43% |
743,018
-537,352
| -42% | -$36.3M |
|
21
Pediatrix Medical
MD
$2.17B
| $57.9M | 2.43% |
3,387,965
+741,765
| +28% | +$11M |
|
22
Thermo Fisher Scientific
TMO
$214B
| $55.1M | 2.31% |
152,180
+92,180
| +154% | +$30.9M |
|
|
NUVA
23
DELISTED
NuVasive, Inc.
NUVA
| $54M | 2.26% |
+969,580
| New | +$56.1M |
|
24
Acadia Pharmaceuticals
ACAD
$4.55B
| $49.7M | 2.08% |
1,025,000
-1,205,474
| -54% | -$57.9M |
|
25
Royalty Pharma
RPRX
$26.2B
| $44.5M | 1.86% |
+916,350
| New | +$45.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2020 Portfolio in Review
As of Q2 2020, HealthCor Management held 68 positions worth $2.39B, up 2% from $2.34B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $369M in Q2 2020, closing 18 positions and reducing 15 holdings. Its most notable exit was Haemonetics, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Cigna worth $88.6M.
- HealthCor Management's largest Q2 2020 buy was Cigna: 472,360 shares worth $88.6M.
- HealthCor Management added most to Becton Dickinson in Q2 2020, an estimated $125M increase.
- HealthCor Management's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $132M.
- HealthCor Management fully exited Haemonetics in Q2 2020, selling an estimated $143M.
- HealthCor Management's ten largest holdings make up 47% of its $2.39B portfolio in Q2 2020.
- HealthCor Management opened 22 new positions and closed 18 in Q2 2020.
- HealthCor Management's portfolio value rose 2% quarter-over-quarter to $2.39B.
Based on HealthCor Management's 13F filing for Q2 2020, filed 14 Aug 2020.